Thrombosis With Thrombocytopenia After mRNA COVID-19 Vaccine Thrombosis With Thrombocytopenia After mRNA COVID-19 Vaccine
What is believed to be the first case of vaccine-induced thrombosis with thrombocytopenia after a messenger RNA COVID-19 vaccine has been reported.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - June 28, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Case reports thrombocytopenia with thrombosis following COVID-19 mRNA vaccine
(American College of Physicians) A single case reports thrombocytopenia with thrombosis syndrome (TTS) following the mRNA-1273 vaccine for COVID-19. Previously, it was hypothesized that adenoviral vector-based vaccines were the sole cause of TTS or vaccine-induced TTS (VITT). The case is published in Annals of Internal Medicine. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 28, 2021 Category: Infectious Diseases Source Type: news
Veralox Therapeutics Announces Closing Of $16.6 Million Series A Financing And Announces New Board Members
FREDERICK, Md., June 16, 2021 -- (Healthcare Sales & Marketing Network) -- Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical... Biopharmaceuticals, Venture Capital Veralox Therapeutics, 12-lipoxygenase, heparin-induced thrombocytopenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 16, 2021 Category: Pharmaceuticals Source Type: news
New Phase 3 Study Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duration of re...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® (daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.[1] These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing and w...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Thrombocytopenia and COVID-19 Severity and Outcome Thrombocytopenia and COVID-19 Severity and Outcome
This systematic review shows that thrombocytopenia is common in COVID-19, and is associated with COVID-19 severity and outcome.Laboratory Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 2, 2021 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news
Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A comp...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Reports New Data for BCMA CAR-T, Cilta-Cel, Showing Deep and Durable Responses in Patients with Relapsed or Refractory Multiple Myeloma
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data for ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen (BCMA)-directed CAR-T therapy, demonstrated sustained efficacy and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM). Updated results from the Phase 1b/2 CARTITUDE-1 study (n=97) with a longer-term follow-up at a median of 18 months showed an overall response rate (ORR) of 98 percent, with 80 percent of patients achieving a stringent complete response (sCR), highlighting ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Mini bone marrow model predicts response to blood disorder treatment
(eLife) A new miniature 3D model of human bone marrow has been described today in the open-access eLife journal. The model may help clinicians predict which patients will benefit from a new therapy for blood platelet disorders, such as Inherited Thrombocytopenias -- a group of familial disorders that inhibit the production of platelets. It could also enable further study of these disorders and give scientists a new tool to test experimental treatments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 1, 2021 Category: International Medicine & Public Health Source Type: news
Eltrombopag may be cost effective for thrombocytopenia and PGF post transplantation
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2021 Category: Drugs & Pharmacology Source Type: news
Single SubQ Shot Offers Fast, Potent Platelet Inhibition in STEMI Single SubQ Shot Offers Fast, Potent Platelet Inhibition in STEMI
The effect was seen within 15 minutes of receiving RUC-4, an investigational glycoprotein IIb/IIIa inhibitor, with no thrombocytopenia, in a phase 2a study.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 26, 2021 Category: Consumer Health News Tags: Cardiology News Source Type: news
Updated Data Demonstrate Significant Improvement in Hematologic Complete Response with DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
RARITAN, N.J., May 26, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated results from the Phase 3 ANDROMEDA study, which evaluated DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare blood cell disorder associated with the deterioration of vital organs, most notably the heart, kidneys and liver.[1] Longer-term results from a median follow-up of 20.3 months showed rates of hematologic complete response (hemCR) remained significantly higher in patients treated with DARZALEX FASPRO® in combi...
Source: Johnson and Johnson - May 26, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
CHMP issues further advice on thrombosis and thrombocytopenia with Vaxzevria (AstraZeneca's COVID-19 vaccine), EMA
Healthcare professionals are advised that Vaxzevria must not be administered to patients with thrombosis with thrombocytopenia syndrome after receiving the vaccine and patients should be monitored for thrombosis and thrombocytopenia within 3 weeks of vaccination. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 25, 2021 Category: Consumer Health News Source Type: news
IMBRUVICA ® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control
May 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the fixed-duration cohort of the investigational Phase 2 CAPTIVATE study, showing that 95 percent of patients treated with combined IMBRUVICA® plus venetoclax were alive and progression-free at two years.[1] Deep remissions were seen across all subgroups, including patients with high-risk chronic lymphocytic leukemia (CLL).1 In addition, long-term data from the RESONATE-2 (PCYC-1115/1116) study will be presented, providing the longest follow-up Phase 3 data for any BTK inhibitor to date. These data ...
Source: Johnson and Johnson - May 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Statins side effects: Unusual bleeding from various body parts could be thrombocytopenia
STATINS side effects: Like all medicines, statins can cause side effects. But most people tolerate them well and do not have any problems. However, some do not and with low blood platelet count being a common side effect from the drug another more serious condition may develop causing unusual bleeding from various body parts. (Source: Daily Express - Health)
Source: Daily Express - Health - May 19, 2021 Category: Consumer Health News Source Type: news
